A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab Together With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 17 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 2018 to 1 jan 2019.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.
- 18 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.